Your browser doesn't support javascript.
loading
Editorial Expression of Concern: Pre-clinical evaluation of cyclin-dependent kinase 2 and 1 inhibition in anti-estrogen-sensitive and resistant breast cancer cells.
Johnson, N; Bentley, J; Wang, L-Z; Newell, D R; Robson, C N; Shapiro, G I; Curtin, N J.
Afiliação
  • Johnson N; Northern Institute for Cancer Research, Newcastle University, Paul O' Gorman Building, Framlington, Newcastle upon Tyne, NE2 4HH, UK.
  • Bentley J; Department of Medical Oncology, Dana-Farber Cancer Institute, 44 Binney Street, Boston, MA, 02115, USA.
  • Wang LZ; Northern Institute for Cancer Research, Newcastle University, Paul O' Gorman Building, Framlington, Newcastle upon Tyne, NE2 4HH, UK.
  • Newell DR; Northern Institute for Cancer Research, Newcastle University, Paul O' Gorman Building, Framlington, Newcastle upon Tyne, NE2 4HH, UK.
  • Robson CN; Northern Institute for Cancer Research, Newcastle University, Paul O' Gorman Building, Framlington, Newcastle upon Tyne, NE2 4HH, UK.
  • Shapiro GI; Northern Institute for Cancer Research, Newcastle University, Paul O' Gorman Building, Framlington, Newcastle upon Tyne, NE2 4HH, UK.
  • Curtin NJ; Department of Medical Oncology, Dana-Farber Cancer Institute, 44 Binney Street, Boston, MA, 02115, USA.
Br J Cancer ; 131(5): 955, 2024 Sep.
Article em En | MEDLINE | ID: mdl-39160248
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias da Mama / Resistencia a Medicamentos Antineoplásicos Limite: Female / Humans Idioma: En Revista: Br J Cancer Ano de publicação: 2024 Tipo de documento: Article País de afiliação: Reino Unido
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias da Mama / Resistencia a Medicamentos Antineoplásicos Limite: Female / Humans Idioma: En Revista: Br J Cancer Ano de publicação: 2024 Tipo de documento: Article País de afiliação: Reino Unido